Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.57 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.52 |
| ▸ | TTK | P33981 | 4/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378166 | 0.93 | MAPK1 (0.66) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL5380115 | 0.92 | MAPK1 (0.56) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL8257261 | 0.88 | MAP3K5 (0.65) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL5375633 | 0.85 | MAP3K5 (0.54) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL5386611 | 0.85 | MAPK1 (0.56) | MAPK1MAP3K5MAPK8CSNK1DMAPK3 | |
| SCHEMBL17801052 | 0.83 | TTK (0.53) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL8258671 | 0.83 | MAPK1 (0.62) | MAPK1MAP3K5TTKCSNK1DMAPK3 | |
| SCHEMBL5387167 | 0.81 | MAP3K5 (0.53) | MAPK1MAP3K5TTKMAPK8CSNK1D | |
| SCHEMBL8252515 | 0.81 | DYRK1A (0.56) | MAP3K5MAPK8CSNK1DMAPK10MAPK14 | |
| SCHEMBL5378125 | 0.80 | CSNK1D (0.56) | MAPK1MAP3K5TTKMAPK8CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAPK1 52/4885MAP3K5 32/4885TTK 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.